Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | DRD3 | P35462 | 4/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270399 | 1.00 | CA12 (0.39) | CA12CA7CA14SMYD3JAK1 | |
| SCHEMBL1679362 | 0.85 | — | — | |
| SCHEMBL4756230 | 0.79 | CA12 (0.42) | CA12CA7CA14JAK1CA1 | |
| SCHEMBL19693509 | 0.79 | CA12 (0.42) | CA12CA7CA14JAK1CA1 | |
| SCHEMBL24940058 | 0.77 | CA12 (0.44) | CA12CA7CA14SMYD3JAK1 | |
| SCHEMBL25131032 | 0.77 | CA12 (0.44) | CA12CA7CA14SMYD3JAK1 | |
| SCHEMBL24043970 | 0.76 | CA12 (0.54) | CA12CA7CA14SMYD3CA1 | |
| SCHEMBL8392209 | 0.76 | CA12 (0.48) | CA12CA7CA14SMYD3CA1 | |
| SCHEMBL12764009 | 0.75 | SMYD3 (0.46) | CA12CA7CA14SMYD3JAK1 | |
| SCHEMBL13438572 | 0.74 | CA12 (0.38) | CA12CA7CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022253309-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | 首药控股(北京)股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20100035996-A1 | GLUCOSE METABOLISM STIMULATING AGENT | SHIONOGI & CO LTD (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035996-A1 | GLUCOSE METABOLISM STIMULATING AGENT | GPR119, GCKR, GHSR | CA12 2972/4885CA7 2100/4885CA14 2784/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | CA12 4343/4885CA7 4334/4885CA14 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.